Antiplatelet Market

Antiplatelet Market by Drugs (Thrombolytic Drugs, Anticoagulants, and Antiplatelet Drugs) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

  • Report ID: HC-2326
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 162
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global antiplatelet market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to the increasing number of chronic diseases that result in thrombosis and the proliferation of anticoagulant drugs. Furthermore, the market growth can be accredited to the availability of generic drugs that are present in the market at low cost.

Antiplatelet Market key takeaways

The phenomenon when blood clots in the blood vessels and remains stuck in the vessel is known as thrombus. In order to reduce these blood clots, antithrombotic agents are used, which can prevent or continue treatment of blood clots. Different blood clotting is affected by different antithrombotics such as thrombolytic drugs, anticoagulants, and antiplatelet drugs. The main application of antithrombotics is to treat the abnormal flow of blood in the human body. Some of the major factors that cause thrombus are smoking, obesity, pregnancy, damage in the blood vessels, inactivity, and genetic & medical conditions.

Individuals who are at high risk of getting a heart attack are given antithrombotic as most of the heart attacks are caused when blood clots happened in the arteries, which are connected to the heart muscles. When people are provided with antiplatelet agents, their risk of having heart attacks or strokes can be avoided. The formation of thrombotic can be prohibited along with a decrease in the platelet aggregation by the usage of antiplatelet drugs, which is a member of a pharmaceutical class. For the prevention of cardiovascular diseases, these agents are widely used. For the treatment & prevention of ischemic events such as stroke, peripheral occlusion, acute coronary syndrome, venous thromboembolism, and myocardial infarction various antithrombotics are used.

Market Trends, Drivers, Restraints, and Opportunities

  • Wide increase in the incidence of hereditary and cardiac diseases is anticipated to fuel the growth of the market during the forecast period.
  • Increasing demand for oral novel anticoagulants along with the increasing geriatric population is expected to propel the growth of the market over the forecast period.
  • Lack of availability of alternatives for antithrombotic drugs and availability of strong drug pipelines are estimated to boost the market growth in the coming years.
  • High cost of novel drugs and issues concerning side effects caused by antithrombotic drugs along with rigid & strict regulatory policies are some key challenges that can restrain the market growth.
  • Pharmaceutical advancements and the development & launch of new products are some major factors that are projected to create profitable opportunities for the market growth.

Scope of the Report

The report on the global antiplatelet market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Antiplatelet Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drugs (Thrombolytic Drugs, Anticoagulants, and Antiplatelet Drugs)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Eli Lilly; Pfizer Inc.; Abbott Laboratories; Novartis; Glaxosmithkline; ONO Pharmaceutical Co. Ltd.; Armetheon Inc.; Baxter International; Astrazeneca; Bayer AG; Microbix Biosystems Inc.; Bristol-Myers Squibb Co.; Emisphere Technologies; Genentech; CSL Behring; Daiichi Sankyo Co. Ltd.; Ligand Pharmaceuticals Inc.; The Medicines Co.; Merck; F.Hoffmann-La Roche AG; Merrion Pharmaceuticals Ltd.; Otsuka Pharmaceutical Co. Ltd.; Biovascular Inc.; Johnson & Johnson; and Boehringer Ingelheim Gmbh

 

Market Segment Insights

Antiplatelet drugs segment is expected to grow at a significant rate

On the basis of drugs, the global antiplatelet market is divided into thrombolytic drugs, anticoagulants, and antiplatelet drugs. The antiplatelet drugs segment is expected to grow at a significant rate during the projected period owing to its wide usage by professionals for long-term prevention. The migration of platelets is reduced or limited by the usage of antiplatelet drugs as they can restrain the process of damage of blood vessel endothelium. The coagulation of blood is prevented by a class of drugs known as anticoagulants. These are naturally present in blood-sucking insects including leeches. Anticoagulants are also used in medical equipment that includes bags for blood transfusion, test tubes, and equipment for renal dialysis. The clots forms in the vessels are dissolved by the usage of thrombolytic drugs and this process is known as thrombolysis. Some of the antiplatelet drugs, anticoagulant drugs, and thrombolytic drugs that are commonly used are Eptifibatide, Abciximab, Glycoprotein IIb/IIIa inhibitors, Certoparin, Bemiparin, Glycosaminoglycans, Factor Xa inhibitor, and r-tPA.

Antiplatelet Market by drugs

Asia Pacific is estimated to expand at a considerable pace

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a significant share of the market in 2019 and is projected to exhibit a high CAGR during the forecast period owing to the presence of well-established healthcare infrastructure, increasing incidence of cardiac disorders, and favorable reimbursement policies in the region. On the other hand, the market of Asia Pacific is estimated to expand at a considerable growth pace in the coming years attributed to the strong availability of the generic drugs and the presence of a high number of cardiac diseases patients in the region.

Antiplatelet Market by Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antiplatelet Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Antiplatelet Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Antiplatelet Market - Supply Chain
  4.5. Global Antiplatelet Market Forecast
     4.5.1. Antiplatelet Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Antiplatelet Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Antiplatelet Market Absolute $ Opportunity
5. Global Antiplatelet Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Antiplatelet Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Antiplatelet Demand Share Forecast, 2019-2026
6. North America Antiplatelet Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Antiplatelet Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Antiplatelet Demand Share Forecast, 2019-2026
7. Latin America Antiplatelet Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Antiplatelet Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Antiplatelet Demand Share Forecast, 2019-2026
8. Europe Antiplatelet Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Antiplatelet Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Antiplatelet Demand Share Forecast, 2019-2026
9. Asia Pacific Antiplatelet Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Antiplatelet Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Antiplatelet Demand Share Forecast, 2019-2026
10. Middle East & Africa Antiplatelet Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Antiplatelet Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Antiplatelet Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Antiplatelet Market: Market Share Analysis
  11.2. Antiplatelet Distributors and Customers
  11.3. Antiplatelet Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Eli Lilly
     11.4.2. Pfizer Inc.
     11.4.3. Abbott Laboratories
     11.4.4. Novartis
     11.4.5. Glaxosmithkline
     11.4.6. ONO Pharmaceutical Co. Ltd.
     11.4.7. Armetheon Inc.
     11.4.8. Baxter International

Segments Covered in the Report
The global antiplatelet market has been segmented on the basis of

Drugs

  • Thrombolytic Drugs
  • Anticoagulants
  • Antiplatelet Drugs

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Eli Lilly
  • Pfizer Inc.
  • Abbott Laboratories
  • Novartis
  • Glaxosmithkline
  • ONO Pharmaceutical Co. Ltd.
  • Armetheon Inc.
  • Baxter International
  • Astrazeneca
  • Bayer AG
  • Microbix Biosystems Inc.
  • Bristol-Myers Squibb Co.
  • Emisphere Technologies
  • Genentech
  • CSL Behring
  • Daiichi Sankyo Co. Ltd.
  • Ligand Pharmaceuticals Inc.
  • The Medicines Co.
  • Merck
  • F.Hoffmann-La Roche AG
  • Merrion Pharmaceuticals Ltd.
  • Otsuka Pharmaceutical Co. Ltd.
  • Biovascular Inc.
  • Johnson & Johnson
  • Boehringer Ingelheim Gmbh

Key players competing in the global antiplatelet market are Eli Lilly; Pfizer Inc.; Abbott Laboratories; Novartis; Glaxosmithkline; ONO Pharmaceutical Co. Ltd.; Armetheon Inc.; Baxter International; Astrazeneca; Bayer AG; Microbix Biosystems Inc.; Bristol-Myers Squibb Co.; Emisphere Technologies; Genentech; CSL Behring; Daiichi Sankyo Co. Ltd.; Ligand Pharmaceuticals Inc.; The Medicines Co.; Merck; F.Hoffmann-La Roche AG; Merrion Pharmaceuticals Ltd.; Otsuka Pharmaceutical Co. Ltd.; Biovascular Inc.; Johnson & Johnson; and Boehringer Ingelheim Gmbh. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.

Antiplatelet Market by key players

Buy Report